Treatment of Vitiligo with the Topical Janus Kinase Inhibitor Ruxolitinib: A 32-Week Open-Label Extension Study with Optional Narrow-Band Ultraviolet B
February 2018
in “
Journal of the American Academy of Dermatology
”
Research cited in this study
1 / 1 results
research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata
This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.
Related Research
4 / 4 resultsresearch Treatment With Oral Janus Kinase Inhibitors in Adult Patients With Alopecia Areata: A Systematic Review and Meta-Analysis
This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.
research Ruxolitinib for the Treatment of Severe Alopecia Areata
This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.
research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata
This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.